Table 2.
Summary of the critical features and characteristics of the RNA, SeV, Epi and Lenti reprogramming methods
| Feature | RNA Stemgent | SeV Life Technologies | Epi Yamanaka/Addgene | Lenti Mostoslavsky/BU |
|---|---|---|---|---|
| Efficiency (fibroblasts) | ~1% | ~0.1% | ~0.01% | ~0.5% |
| Reliability (fibroblasts) | <50% (miRNA + mRNA: >70%) | >90% | >90% | >90% |
| Reprogramming workload | High | Low | Low | Very high (excision) |
| Aneuploidy rate | 2.3% | 4.6% | 11.5% | 4.5% |
| Input cell requirement (fibroblasts) | ~50 k | ~500 k | ~500–800 k | ~100 k |
| Time to colony emergence | Fast | Moderate | Moderate | Moderate |
| Adoption rate (fibroblasts) | 46% | 62% | 33% | 19% |
| Efficiency (blood) | Not yet reported | High | High | High |
| Reliability (blood) | Not yet reported | High | High | High |
| Adoption rate (blood) | Not yet reported | 61% | 44% | 40% |
| Special equipment needs | 5% O2 incubator | None | Transfection device, and O2 incubator (blood) | None |
| Lines free of reprogramming agents by passage 5 | 100% | 0% (Cytotune 1) | 60.9% | 0% |
| Lines free of reprogramming agents by passage 9–11 | 100% | 78.8% | 66.7% | 0% |
| Xeno-free cGMP-like reprogramming | (Ref. 10) | (Ref. 25) | (Refs. 8,27) see also Supplementary Figure 7 | (Ref. 26) |